Liquidia to Participate at H.C. Wainwright 23rd Annual Global Investment Conference
10 September 2021 - 10:29PM
Liquidia Corporation (NASDAQ: LQDA) announced today that Damian
deGoa, Chief Executive Officer, will present at the H.C. Wainwright
23rd Annual Global Investment Conference, which runs from September
13 – 15, 2021. The conference will be held in a virtual format.
The presentation will be available on-demand in the Investors
section of Liquidia’s website at
https://liquidia.com/investors/events-and-presentations starting at
7:00 a.m. ET on Monday, September 13, 2021, and available for 30
days following the conference.
About Liquidia CorporationLiquidia
Corporation is a biopharmaceutical company focused on the
development and commercialization of products in pulmonary
hypertension and other applications of its PRINT® Technology. The
company operates through its two wholly owned subsidiaries,
Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia
Technologies is developing LIQ861, an inhaled dry powder
formulation of treprostinil for the treatment of pulmonary arterial
hypertension (PAH). Liquidia PAH provides the commercialization for
rare disease pharmaceutical products, such as generic Treprostinil
Injection. For more information, please visit www.liquidia.com.
Contact InformationMedia &
Investors:Jason AdairVice President, Corporate Development
and Strategy919.328.4400jason.adair@liquidia.com
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Apr 2024 to May 2024
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From May 2023 to May 2024